VJHemOnc is committed to improving our service to you

SOHO 2020 | Spleen volume responses in fedratinib treated myelofibrosis patients

VJHemOnc is committed to improving our service to you

Ruben Mesa

Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, outlines the spleen volume responses as assessed in the JAKARTA study (NCT01437787), where patients with myelofibrosis were treated with fedratinib, a JAK inhibitor. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter